Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
© 2017 Informa UK Limited, trading as Taylor & Francis Group. Objective: With the advent of the anaplastic lymphoma kinase (ALK) inhibitor, treatment of ALK-positive advanced non-small-cell lung cancer (NSCLC) patients has become more effective while drug costs are still a major concern. This...
Saved in:
| Main Authors: | , |
|---|---|
| 格式: | 雜誌 |
| 出版: |
2017
|
| 在線閱讀: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85015768144&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/40463 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
| 機構: | Chiang Mai University |